Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $IMNM
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/8/2024 | $30.00 | Overweight | Stephens |
5/31/2024 | $27.00 | Overweight | Piper Sandler |
4/30/2024 | $24.00 | Overweight | JP Morgan |
4/15/2024 | $35.00 | Buy | Guggenheim |
1/29/2024 | $30.00 | Outperform | Leerink Partners |
12/19/2023 | $12.00 | Outperform | Wedbush |
10/29/2021 | $35.00 | Overweight | Cantor Fitzgerald |
Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
Co-founder Susan Dillon, Ph.D., to remain as the chair of Board of Directors Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its co-founder, Susan Dillon, Ph.D., will transition from her position as president and chief executive officer (CEO) and continue as chair of the Board of Directors and advisor to the company. As part of the planned leadership transition, Aro appointed industry veteran Purnanand Sarma, Ph.D., as the CEO and a member of the Board, effective immediately. "We founded Aro with the vision to create a new class of targeted siRNA medicines to address significant
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. (the "Company") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 3, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 51,000 shares of common stock to four new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to
Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Immunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the closing of its underwritten public offering of 22,258,064 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,903,225 shares, at a price to the public of $7.75 per share. The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses, were $172.5 million. All of the shares in the offering were sold by Immunome. J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities acted as join
Stephens initiated coverage on Immunome with a new price target
Stephens initiated coverage of Immunome with a rating of Overweight and set a new price target of $30.00
Piper Sandler initiated coverage on Immunome with a new price target
Piper Sandler initiated coverage of Immunome with a rating of Overweight and set a new price target of $27.00
JP Morgan initiated coverage on Immunome with a new price target
JP Morgan initiated coverage of Immunome with a rating of Overweight and set a new price target of $24.00
President and CEO Siegall Clay B bought $1,162,500 worth of shares (150,000 units at $7.75), increasing direct ownership by 29% to 669,636 units (SEC Form 4)
4 - Immunome Inc. (0001472012) (Issuer)
President and CEO Siegall Clay B bought $962,181 worth of shares (100,000 units at $9.62), increasing direct ownership by 24% to 519,636 units (SEC Form 4)
4 - Immunome Inc. (0001472012) (Issuer)
Chief Medical Officer Lechleider Robert bought $149,800 worth of shares (15,805 units at $9.48) (SEC Form 4)
4 - Immunome Inc. (0001472012) (Issuer)
President and CEO Siegall Clay B bought $1,162,500 worth of shares (150,000 units at $7.75), increasing direct ownership by 29% to 669,636 units (SEC Form 4)
4 - Immunome Inc. (0001472012) (Issuer)
President and CEO Siegall Clay B bought $962,181 worth of shares (100,000 units at $9.62), increasing direct ownership by 24% to 519,636 units (SEC Form 4)
4 - Immunome Inc. (0001472012) (Issuer)
Chief Medical Officer Lechleider Robert bought $149,800 worth of shares (15,805 units at $9.48) (SEC Form 4)
4 - Immunome Inc. (0001472012) (Issuer)
Amendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.
SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)
Amendment: SEC Form SCHEDULE 13D/A filed by Immunome Inc.
SCHEDULE 13D/A - Immunome Inc. (0001472012) (Subject)
Amendment: SEC Form SCHEDULE 13G/A filed by Immunome Inc.
SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)
Aro Biotherapeutics Announces Leadership Transition and Appoints Purnanand Sarma, Ph.D., as Chief Executive Officer
Co-founder Susan Dillon, Ph.D., to remain as the chair of Board of Directors Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent, targeted short-interfering RNA (siRNA) medicines, today announced that its co-founder, Susan Dillon, Ph.D., will transition from her position as president and chief executive officer (CEO) and continue as chair of the Board of Directors and advisor to the company. As part of the planned leadership transition, Aro appointed industry veteran Purnanand Sarma, Ph.D., as the CEO and a member of the Board, effective immediately. "We founded Aro with the vision to create a new class of targeted siRNA medicines to address significant
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Company. "Roee further strengthens an Immunome team whose members have designed, developed and commercialized innovative targeted therapies for cancer patients," stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome.
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
Press Release Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics Geneva, Switzerland – July 9, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today the appointment of Dr. Purnanand Sarma, PhD, as Chair of its Board of Directors. Dr. Sarma, who will hold the title of Executive Chairman, will actively support the strategic development of STALICLA, working closely with the CEO, Lynn Durham, and the management team. With an
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
Topline data for Phase 3 RINGSIDE trial of AL102 expected in first quarter of 2025 IM-1021 and IM-3050 IND filings expected in first quarter of 2025 Current cash expected to fund activities into 2026 Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2023, and provided an overview of recent developments. "2023 was a transformative year for Immunome as we closed the merger with Morphimmune, advanced our pipeline and expanded the company's leadership team," said Clay B. Siegall, Ph.D., President and Chief Executive Officer. "Th
Immunome Reports Third Quarter 2023 Financial Results
- Completed merger with Morphimmune and concurrent $125 million private placement investment with leading institutional investors - - Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO - - Bob Lechleider, M.D., appointed as Chief Medical Officer – - Jean-Jacques Bienaimé, former CEO of BioMarin appointed as member of the Board of Directors - - Cash runway expected to extend into Q1 2026* - Immunome, Inc. (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
Immunome Reports Fourth Quarter and Full Year 2022 Financial Results
Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31, 2022 and provided a corporate update. "Looking back on the past year, the transformative strategic collaboration with AbbVie highlighted the disruptive nature of our discovery platform in finding novel antibody-target pairs based on human memory B-cell response," stated Purnanand Sarma, Ph.D., President and CEO of Immunome. "We look forward to continuing to execute on our momentum throughout the upcoming year as we advance our p
Amendment: SEC Form SC 13G/A filed by Immunome Inc.
SC 13G/A - Immunome Inc. (0001472012) (Subject)
SEC Form SC 13G filed by Immunome Inc.
SC 13G - Immunome Inc. (0001472012) (Subject)
SEC Form SC 13G filed by Immunome Inc.
SC 13G - Immunome Inc. (0001472012) (Subject)